To this end, we first analyzed the expression of NALCN mRNA in aza-treated cell lines and then examined the methylation status of the NALCN promoter in NSCLC tissues, adjacent non-cancerous tissues, and ctDNA, as well as in healthy individuals. Here, NALCN is linked to non-small cell lung carcinoma.